Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract.

Mechan AO, Fowler A, Seifert N, Rieger H, Wöhrle T, Etheve S, Wyss A, Schüler G, Colletto B, Kilpert C, Aston J, Elliott JM, Goralczyk R, Mohajeri MH.

Br J Nutr. 2011 Apr;105(8):1150-63. doi: 10.1017/S0007114510004940. Epub 2010 Dec 21.

PMID:
21205415
2.

A comparison of learning and memory characteristics of young and middle-aged wild-type mice in the IntelliCage.

Mechan AO, Wyss A, Rieger H, Mohajeri MH.

J Neurosci Methods. 2009 May 30;180(1):43-51. doi: 10.1016/j.jneumeth.2009.02.018. Epub 2009 Mar 10.

PMID:
19427528
3.

Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.

Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD.

J Pharmacol Exp Ther. 2005 Oct;315(1):91-8. Epub 2005 Jul 13.

PMID:
16014752
4.

Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons.

Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, Ricaurte GA.

J Neurosci. 2004 Aug 11;24(32):7043-50.

5.

Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain.

Beveridge TJ, Mechan AO, Sprakes M, Pei Q, Zetterstrom TS, Green AR, Elliott JM.

Psychopharmacology (Berl). 2004 May;173(3-4):346-52. Epub 2004 Jan 20.

PMID:
14735293
6.

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.

Pharmacol Rev. 2003 Sep;55(3):463-508. Epub 2003 Jul 17. Review.

PMID:
12869661
8.

A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam.

Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, Green R.

Psychopharmacology (Berl). 2002 Jan;159(2):188-95. Epub 2001 Sep 22.

PMID:
11862348
9.

A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field.

Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, Green R.

Psychopharmacology (Berl). 2002 Jan;159(2):167-75. Epub 2001 Oct 3.

PMID:
11862345
10.

The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.

Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR.

Br J Pharmacol. 2002 Jan;135(1):170-80.

11.

A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain.

Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR.

Br J Pharmacol. 2001 Dec;134(8):1711-23.

12.

A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation.

Mechan AO, O'Shea E, Elliott JM, Colado MI, Green AR.

Psychopharmacology (Berl). 2001 Jun;155(4):413-8.

PMID:
11441431
13.

Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.

Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM.

Exp Neurol. 1999 Mar;156(1):92-9.

PMID:
10192780

Supplemental Content

Loading ...
Support Center